<DOC>
	<DOCNO>NCT02729714</DOCNO>
	<brief_summary>The purpose study see study drug , suvorexant , safe effective treating symptom insomnia people Parkinson 's Disease . It anticipate total 20 subject , 30 80 year age , Parkinson 's Disease symptom insomnia participate study site</brief_summary>
	<brief_title>A Pilot Study Suvorexant Insomnia Parkinson Disease</brief_title>
	<detailed_description>The propose study randomize , double-blind , placebo-controlled , cross-over trial ass safety , tolerability , efficacy suvorexant specifically cohort 20 Parkinson 's Disease patient age 30 80 ( inclusive ) complaint insomnia . After informed consent give , potential subject screen ensure meet eligibility criterion . This include overnight polysomnogram , serve baseline screening polysomnogram . Active drug suvorexant 10 mg orally bed time optional up-titration 15 mg orally bedtime 2 week . The first treatment period 4 week long , subject randomize 1:1 receive active drug match placebo . At end treatment period 1 , subject undergo efficacy assessment repeat polysomnogram clinical scale . This follow 2-week washout period placebo ; period single-blinded , subject blind treatment . Subjects crossed alternate treatment group , double-blinded ; active treatment period 1 switch placebo , placebo period 1 switch active treatment . Treatment period 2 also 4 week long , end , subject undergo final assessment polysomnogram clinical scale .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Has sign date Institutional Review Boardapproved inform consent form protocolspecific screening procedure perform ; Has diagnosis Parkinson disease accord United Kingdom Parkinson Disease Society Brain Bank Criteria ; Has modify Hoehn Yahr Stage 13 , inclusive ; Is age 3080 year old , inclusive ; Has change Parkinson 's Disease medication 4 week precede screening , dose change study , except need dos carbidopa/levodopa allow address periodic worsen parkinsonian symptom ; Is willing able complete polysomnogram ; Is subject willing able limit alcohol use 1 alcoholic drink per day study period abstain alcohol 6 hour prior studyrelated polysomnogram ? Is subject willing able abstain caffeine marijuana 6 hour prior studyrelated polysomnogram Is subject willing able abstain product contain nicotine studyrelated polysomnogram ? Has Insomnia Disorder define diagnostic criterion publish Diagnostic Statistical Manual Mental Disorders , 5th edition ; namely , subject report follow : One following : difficulty initiate sleep ; difficulty maintain sleep ; early morning waking ; Sleep disturbance cause clinically significant distress impairment social , occupational , educational , academic , behavioral , important area function ; Sleep difficulty occur 3 night per week ; Sleep difficulty present least past 3 month ; Sleep difficulty occur despite adequate opportunity sleep ; Insomnia explain another sleep disorder ; Insomnia attributable physiological effect consume substance ; On screen polysomnogram , latency persistent sleep &gt; 20 minute OR total wakefulness sleep onset &gt; 45 minute ; May use medication could influence sleep , specifically prohibit , long dose stable 4 week precede screening , dose change study ; Has valid health insurance coverage time study enrollment expect coverage remain valid duration study period . Is woman breastfeed , pregnant , potential become pregnant course study ( fertile unwilling/unable use effective contraceptive measure ) ; Does subject implant deep brain stimulator ? Has history narcolepsy ; Has diagnosis severe chronic obstructive pulmonary disease , define forced expiratory volume 1 second &lt; 50 % predict recent available pulmonary function test ( pulmonary function test require subject never diagnose chronic obstructive pulmonary disease ) ; Has history severe obstructive sleep apnea evidence severe obstructive sleep apnea screen polysomnogram , severe obstructive sleep apnea define apneahypopnea index &gt; 30 ; Is concurrently use central nervous system depressant , include alcohol , except one alcoholic drink per day allow normal hepatic function provide drink consume least 2 hour prior 8 hour take study drug , alcohol permit 24 hour polysomnogram visit ; Is concurrently use digoxin ; Is concurrently use moderate strong inhibitor cytochrome P450 3A ; Is concurrently use strong inducer cytochrome P450 3A ; Has evidence screen severe hepatic impairment define ChildPugh score &gt; 10 ; Has evidence screen severe cognitive impairment define Montreal Cognitive Assessment score &lt; 15 , cognitive impairment opinion investigator would prevent completion study procedure ability provide inform consent . Has evidence screen suicidal ideation past 6 month define positive response one Questions 25 Columbia Suicide Severity Rating Scale lifetime history suicidal behavior define positive response suicidal behavior section Columbia Suicide Severity Rating Scale .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>